Chimeric antigen receptor (CAR) T-cell ("Living Drug") immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year. Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside and back to bench – constructing, manufacturing and obtaining FDA approvals for clinical grade CARs and vectors, developing universal algorithms across multiple CAR T-cell clinical trials for the treatment and management of complications, and conducting world-class correlative science.

MSK faculty, along with national and international experts, will discuss the clinical and translational aspects of cell therapies (CARs, TCRs, NKs), both for hematologic malignancies and solid tumors.

The target audience includes medical oncologists and oncology fellows, basic scientists, research fellows, nurses, clinical trial research staff, immunologists, and surgeons with an interest in tumor immunology and immunotherapy.

Main Sessions Topics

• Building a clinical CAR T-cell program
• Mechanisms of Relapse in CD19 CAR T-cell therapies
• Solid tumor cell therapy clinical trials
• Toxicity management in clinic
• Next-gen CARs for hematological malignancies
• Off-the shelf cell therapies
• Biomarkers and novel assays for cell therapy monitoring
• Manufacturing processes for cell engineering
• Navigating the IP and licensing landscape

Breakout Session Topics

• Meet the experts session
• Case studies & Rapid-fire presentations
• ABC of Cell Therapy for paramedical staff
• Novel gene engineering in cell therapies
• Operational infrastructure of commercial cell therapies

Call for Abstracts

Participants are invited to submit an abstract for presentation at the course. Abstracts for the poster session will be selected on the basis of scientific merit and content quality. To submit an abstract for presentation, please select 'Abstracts' above. Submission deadline: January 31, 2019. International presenters will be notified by January 2, 2019 to assist with making travel arrangements.

1. To learn new developments in CAR T-cell therapy
2. To learn patient toxicity management
3. To learn patient clinical trial management algorithms

*Early Registration - Apply promo code CARTC19E at checkout (deadline: January 31, 2019)
**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. Please click here for more information or email cme@mskcc.org if you have additional questions.

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

Registration Discounts/Promotions

• MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
• MSK Employee Registration Waitlist. MSK staff interested in registering for this course should join the waitlist. We will notify you before the course if space is available.
  

Please note: after your payment has been processed, no further promotional discount adjustments will be made to your registration.

Cancellation Policy

If you cancel your participation in this course, your registration fee, less a $75 administrative fee, will be refunded when email notification is received by the MSK Office of Continuing Medical Education (MSK CME) at least 7 days prior to the first day of the course (cme@mskcc.org).

Cancellations or no-shows after this date are not eligible for a refund. MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, we will refund the registration fee in full, but are not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies. At any time, you may substitute another registrant in your place after contacting MSK CME with the relevant information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

MSK Course Director

Prasad S. Adusumilli, MD, FACS, FCCP   
Head, Solid Tumors Cell therapy, Center for Cellular Therapeutics
Member, Center for Cell Engineering 
Deputy Chief, Thoracic Surgery Service, Dept. of Surgery

MSK Co-Course Directors

Renier J. Brentjens, MD, PhD
Director, Cellular Therapeutics Center
Associate Attending
Leukemia Service
Division of Hematologic Oncology
Department of Medicine

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Member, Immunology Program
Member, Departments of Medicine and Pediatrics 

Course schedule and complete faculty list will be available soon. 

Abstract Submission

Memorial Sloan Kettering Cancer Center (MSK) is pleased to invite you to submit an abstract for poster presentation at our Clinical Application of CAR T Cells Conference.

Abstracts will be selected for the poster session on the basis of their scientific merit and content quality.

Submission Deadline

Materials must be received by MSK by 11:59 pm EST on January 31, 2019.